Estados financieros detallados de Dogwood Therapeutics, Inc. (DWTX): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $1.70, DWTX presenta beneficios negativos (P/E no significativo) y un ROE del -47.85%. La capitalización bursátil es de $57M.
Cuenta de Resultados (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| I+D | $854109 | $800620 | $194013 | $10.8M | $8.1M | $1.7M | $3.5M | $21.9M |
| Generales y Administrativos | $1.1M | $1.4M | $9.8M | $4.8M | $4.2M | $3.7M | $8.7M | $6.1M |
| Gastos Operativos | $2.0M | $2.2M | $10.0M | $15.6M | $12.3M | $5.4M | $12.2M | $28.0M |
| Beneficio Operativo | -$2.0M | -$2.2M | -$10.0M | -$15.6M | -$12.3M | -$5.4M | -$12.2M | -$28.0M |
| EBITDA | -$2.0M | -$2.2M | -$10.0M | -$16.0M | -$12.2M | -$5.3M | -$12.2M | -$34.0M |
| Gastos por Intereses | $152103 | $295128 | $384222 | 0 | 0 | 0 | $92192 | 0 |
| Beneficio Antes de Impuestos | -$2.1M | -$2.5M | -$10.3M | -$16.0M | -$12.2M | -$5.3M | -$12.4M | -$34.0M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | -$503 | $221096 |
| Beneficio Neto | -$2.1M | -$2.5M | -$10.3M | -$16.0M | -$12.2M | -$5.3M | -$12.3M | -$34.3M |
| BPA | $-10.93 | $-12.80 | $-52.50 | $-47.90 | $-27.66 | $-7.05 | $-12.52 | $-4.32 |
| BPA Diluido | $-10.93 | $-12.80 | $-52.50 | $-47.90 | $-27.66 | $-7.05 | $-12.52 | $-4.32 |
| Acciones en Circulación (Diluidas) | $193299 | $193299 | $197079 | $333172 | $442804 | $751071 | $1.0M | $8.2M |
Balance (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $30026 | $309384 | $29.8M | $14.0M | $7.0M | $3.3M | $14.8M | $6.5M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | $334 | $785 | $324 | 0 | 0 | 0 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $42398 | $315900 | $31.5M | $15.8M | $8.4M | $4.2M | $16.5M | $8.4M |
| Inmovilizado Material | 0 | 0 | 0 | 0 | 0 | 0 | $222648 | $194931 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | $11.8M | $12.4M |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | $65.7M | $69.0M |
| Activos Totales | $65935 | $315900 | $31.5M | $15.8M | $8.4M | $4.2M | $94.3M | $90.2M |
| Cuentas por Pagar | $145656 | $35421 | $368905 | $353863 | $573164 | $111913 | $1.2M | $760945 |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $1.3M | $1.6M | $1.5M | $1.3M | $1.0M | $358548 | $3.2M | $3.1M |
| Deuda a Largo | 0 | $3.6M | 0 | 0 | 0 | 0 | $15.4M | 0 |
| Pasivos Totales | $1.3M | $5.3M | $1.5M | $1.3M | $1.0M | $358548 | $30.0M | $15.3M |
| Reservas | -$15.1M | -$17.6M | -$28.0M | -$43.9M | -$56.2M | -$61.5M | -$73.8M | -$108.1M |
| Patrimonio Neto | -$1.3M | -$4.9M | $29.9M | $14.5M | $7.3M | $3.8M | $64.3M | $74.9M |
| Deuda Total | 0 | $3.6M | 0 | 0 | 0 | 0 | $15.6M | $162604 |
| Deuda Neta | -$30026 | $3.3M | -$29.8M | -$14.0M | -$7.0M | -$3.3M | $737709 | -$6.4M |
| Capital Circulante | -$1.3M | -$1.3M | $29.9M | $14.5M | $7.3M | $3.8M | $13.4M | $5.4M |
Flujo de Caja (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$2.1M | -$2.5M | -$10.3M | -$16.0M | -$12.2M | -$5.3M | -$12.3M | -$34.3M |
| Amortizaciones | 0 | 0 | 0 | 0 | 0 | 0 | $12177 | $2063 |
| Compensación en Acciones | 0 | 0 | $7.4M | $322881 | $582659 | $619972 | $476021 | $355642 |
| Cambio en Capital Circulante | $869132 | $316476 | -$974060 | -$52191 | $197378 | -$194446 | -$581268 | -$133004 |
| Flujo de Caja Operativo | -$1.2M | -$2.1M | -$3.9M | -$15.7M | -$11.5M | -$4.9M | -$8.8M | -$15.6M |
| Inversiones (CapEx) | 0 | 0 | -$5 | 0 | -$3 | 0 | $5 | 0 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | $3.8M | 0 |
| Recompra de Acciones | 0 | 0 | 0 | -$295166 | 0 | 0 | -$351 | 0 |
| Dividendos Pagados | 0 | 0 | -$75000 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$1.2M | -$2.1M | -$3.9M | -$15.7M | -$11.5M | -$4.9M | -$8.8M | -$15.6M |
Crecimiento y Márgenes (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Crecimiento Beneficio Neto (anual) | -17.0% | -318.3% | -54.3% | +23.3% | +56.8% | -133.2% | -177.4% | |
| Crecimiento BPA (anual) | -17.1% | -310.2% | +8.8% | +42.3% | +74.5% | -77.6% | +65.5% | |
| Cambio en Acciones (anual) | +0.0% | +2.0% | +69.1% | +32.9% | +69.6% | +36.8% | +699.8% | |
| Crecimiento FCF (anual) | -74.9% | -86.2% | -302.8% | +26.9% | +57.5% | -80.5% | -77.7% | |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | 0.0% | -0.6% |
Datos por Acción (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| FCF por Acción | $-6.19 | $-10.82 | $-19.76 | $-47.09 | $-25.90 | $-6.48 | $-8.55 | $-1.90 |
| Dividendo por Acción | $0.00 | $0.00 | $0.38 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $193299 | $193299 | $197079 | $333172 | $442804 | $751071 | $1.0M | $8.2M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -47.85% |
| Rentabilidad sobre capital invertido | -35.62% |
| Rentabilidad sobre activos | -44.77% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.00 |
| Ratio corriente | 3.89 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -1.29 |
Ratios Clave (10 años)
| Año | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| P/E | -38.22 | -32.64 | -3.58 | -2.67 | -0.21 | -2.04 | -0.20 | -0.96 |
| P/VC | -64.07 | -16.34 | 1.24 | 2.94 | 0.36 | 2.84 | 0.04 | 0.46 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Empresas relacionadas: BOLT · BRTX · CLRB · COCP · EDSA · ERNA · EVGN
Explorar sector: Healthcare · Biotechnology
Más secciones de DWTX: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones